Cargando…

484 Allergen Standardisation in Allergens and Allergoids—Challenges and Considerations

BACKGROUND: The range of therapeutics and dosing schedules for allergen preparations and allergoids produced and used clinically are considerable. Standardisation of allergy immunotherapies is considered a positive step; however there are difficulties in identifying universal metrics for standardisa...

Descripción completa

Detalles Bibliográficos
Autores principales: Skinner, Murray, Bullimore, Alan, Hewings, Simon, Swan, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization Journal 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512696/
http://dx.doi.org/10.1097/01.WOX.0000411599.19938.c1
_version_ 1782251780508221440
author Skinner, Murray
Bullimore, Alan
Hewings, Simon
Swan, Nicola
author_facet Skinner, Murray
Bullimore, Alan
Hewings, Simon
Swan, Nicola
author_sort Skinner, Murray
collection PubMed
description BACKGROUND: The range of therapeutics and dosing schedules for allergen preparations and allergoids produced and used clinically are considerable. Standardisation of allergy immunotherapies is considered a positive step; however there are difficulties in identifying universal metrics for standardisation. Many advocate the use of major allergen content whilst others advocate total allergenicity. Additionally as a compounding argument, where major allergen is used, many disagree on what the major allergen is for certain species. METHODS: Major allergen content measurement allows a consistent recognised measure, and IgE responses of a serum pool are often dominated by IgE against major allergens. However issues such as specificity of different assays toward isoforms and other variants of single allergens often results in diverging allergen contents that can cause unexpected and misleading disparity. Other aspects that increase complication are the relevance to modified allergens, use of adjuvants and differing dosing regimes. RESULTS: The major allergen content of key products in different therapeutic formats has been measured. CONCLUSIONS: This has been performed in conjunction with techniques such as total allergenicity, as allergy treatments and therapeutics require careful characterisation to allow supply of consistent, safe and efficacious products.
format Online
Article
Text
id pubmed-3512696
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher World Allergy Organization Journal
record_format MEDLINE/PubMed
spelling pubmed-35126962012-12-21 484 Allergen Standardisation in Allergens and Allergoids—Challenges and Considerations Skinner, Murray Bullimore, Alan Hewings, Simon Swan, Nicola World Allergy Organ J Abstracts of the XXII World Allergy Congress BACKGROUND: The range of therapeutics and dosing schedules for allergen preparations and allergoids produced and used clinically are considerable. Standardisation of allergy immunotherapies is considered a positive step; however there are difficulties in identifying universal metrics for standardisation. Many advocate the use of major allergen content whilst others advocate total allergenicity. Additionally as a compounding argument, where major allergen is used, many disagree on what the major allergen is for certain species. METHODS: Major allergen content measurement allows a consistent recognised measure, and IgE responses of a serum pool are often dominated by IgE against major allergens. However issues such as specificity of different assays toward isoforms and other variants of single allergens often results in diverging allergen contents that can cause unexpected and misleading disparity. Other aspects that increase complication are the relevance to modified allergens, use of adjuvants and differing dosing regimes. RESULTS: The major allergen content of key products in different therapeutic formats has been measured. CONCLUSIONS: This has been performed in conjunction with techniques such as total allergenicity, as allergy treatments and therapeutics require careful characterisation to allow supply of consistent, safe and efficacious products. World Allergy Organization Journal 2012-02-17 /pmc/articles/PMC3512696/ http://dx.doi.org/10.1097/01.WOX.0000411599.19938.c1 Text en Copyright © 2012 by World Allergy Organization
spellingShingle Abstracts of the XXII World Allergy Congress
Skinner, Murray
Bullimore, Alan
Hewings, Simon
Swan, Nicola
484 Allergen Standardisation in Allergens and Allergoids—Challenges and Considerations
title 484 Allergen Standardisation in Allergens and Allergoids—Challenges and Considerations
title_full 484 Allergen Standardisation in Allergens and Allergoids—Challenges and Considerations
title_fullStr 484 Allergen Standardisation in Allergens and Allergoids—Challenges and Considerations
title_full_unstemmed 484 Allergen Standardisation in Allergens and Allergoids—Challenges and Considerations
title_short 484 Allergen Standardisation in Allergens and Allergoids—Challenges and Considerations
title_sort 484 allergen standardisation in allergens and allergoids—challenges and considerations
topic Abstracts of the XXII World Allergy Congress
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512696/
http://dx.doi.org/10.1097/01.WOX.0000411599.19938.c1
work_keys_str_mv AT skinnermurray 484allergenstandardisationinallergensandallergoidschallengesandconsiderations
AT bullimorealan 484allergenstandardisationinallergensandallergoidschallengesandconsiderations
AT hewingssimon 484allergenstandardisationinallergensandallergoidschallengesandconsiderations
AT swannicola 484allergenstandardisationinallergensandallergoidschallengesandconsiderations